MX2019006189A - Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea. - Google Patents
Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea.Info
- Publication number
- MX2019006189A MX2019006189A MX2019006189A MX2019006189A MX2019006189A MX 2019006189 A MX2019006189 A MX 2019006189A MX 2019006189 A MX2019006189 A MX 2019006189A MX 2019006189 A MX2019006189 A MX 2019006189A MX 2019006189 A MX2019006189 A MX 2019006189A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- drug
- hormone receptor
- parathyroid hormone
- targeting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428492P | 2016-11-30 | 2016-11-30 | |
| US201762553313P | 2017-09-01 | 2017-09-01 | |
| PCT/US2017/064081 WO2018102616A1 (en) | 2016-11-30 | 2017-11-30 | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019006189A true MX2019006189A (es) | 2019-11-18 |
Family
ID=62241919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006189A MX2019006189A (es) | 2016-11-30 | 2017-11-30 | Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20200317745A1 (enExample) |
| EP (1) | EP3548012A4 (enExample) |
| JP (2) | JP7649624B2 (enExample) |
| CN (1) | CN110114065A (enExample) |
| AU (1) | AU2017367699B2 (enExample) |
| BR (1) | BR112019011070A2 (enExample) |
| CA (1) | CA3045458A1 (enExample) |
| IL (1) | IL266977B2 (enExample) |
| MX (1) | MX2019006189A (enExample) |
| WO (1) | WO2018102616A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3045458A1 (en) * | 2016-11-30 | 2018-06-07 | Purdue Research Foundation | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
| EP3796941A4 (en) * | 2018-05-30 | 2022-12-28 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| CN110551201B (zh) * | 2019-08-26 | 2020-04-28 | 杭州彗搏科技有限公司 | 一种新型骨形成蛋白2来源的环肽、制备方法及其应用 |
| CN114364327A (zh) * | 2019-09-12 | 2022-04-15 | 雷迪厄斯健康公司 | 用阿巴帕肽改善脊柱融合的方法 |
| CN112646042A (zh) * | 2019-10-10 | 2021-04-13 | 陕西麦科奥特科技有限公司 | 活性多肽化合物 |
| WO2022051555A2 (en) * | 2020-09-03 | 2022-03-10 | Rampart Bioscience, Inc. | Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs |
| WO2022093373A1 (en) * | 2020-10-26 | 2022-05-05 | Purdue Research Foundation | Compounds,compositions and methods of use to treat bone fractures |
| JP2023547889A (ja) * | 2020-10-26 | 2023-11-14 | パーデュー・リサーチ・ファウンデーション | 脊椎融合を治療するための化合物、組成物、および使用の方法 |
| AU2022205801A1 (en) * | 2021-01-05 | 2023-07-13 | Radius Health, Inc. | Treatment of long bone fractures with abaloparatide |
| WO2023136866A1 (en) * | 2022-01-14 | 2023-07-20 | Novosteo Llc | Bone targeted treatment in osteogenesis imperfecta |
| WO2024246840A1 (en) * | 2023-06-01 | 2024-12-05 | Radius Health, Inc. | Methods for identification and quantitation of abaloparatide and related peptide impurities |
| WO2025019691A1 (en) * | 2023-07-19 | 2025-01-23 | Zymeron Corporation | Drug conjugates for bone marrow protection |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9103791A (en) * | 1990-12-21 | 1992-07-22 | Allelix Biopharmaceuticals Inc. | Oxidation resistant variants of parathyroid hormone |
| WO1995002610A1 (en) * | 1993-07-13 | 1995-01-26 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
| EP1950224A3 (en) * | 1998-03-09 | 2008-12-17 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| US7057012B1 (en) * | 1998-12-31 | 2006-06-06 | The General Hospital Corporation | PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
| JP2000327583A (ja) | 1999-05-17 | 2000-11-28 | Medei Sci Puraningu:Kk | 骨指向性ホルモン誘導体 |
| WO2004062588A2 (en) * | 2003-01-06 | 2004-07-29 | University Of Utah | Water-soluble polymeric bone-targeting drug delivery system |
| HUE055861T2 (hu) | 2004-04-21 | 2021-12-28 | Alexion Pharma Inc | Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez |
| US7863238B2 (en) | 2004-06-10 | 2011-01-04 | Saint Louis University | Proteins with an attached short peptide of acidic amino acids |
| US20110046059A1 (en) * | 2005-09-06 | 2011-02-24 | Zelos Therapeutics, Inc. | Pharmaceutically acceptable formulations/compositions for peptidyl drugs |
| US7803770B2 (en) * | 2006-10-03 | 2010-09-28 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
| JP5375611B2 (ja) | 2006-10-03 | 2013-12-25 | ラジウス ヘルス,インコーポレイテッド | 骨同化作用を有するタンパク質のための薬物送達方法 |
| DK2155874T3 (en) * | 2007-04-09 | 2016-08-01 | Univ Arkansas | FUSION PROTEIN OF COLLAGE BINDING DOMAIN AND parathyroid hormone |
| PL2158319T4 (pl) * | 2007-05-11 | 2016-04-29 | Alexion Pharma Inc | Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie |
| WO2009141823A2 (en) * | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases |
| WO2012111852A1 (ja) * | 2011-02-17 | 2012-08-23 | 帝人ファーマ株式会社 | 椎体骨折治療剤及びその評価方法 |
| US20130006217A1 (en) * | 2011-04-22 | 2013-01-03 | Gary Hattersley | METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES |
| CN102824647B (zh) * | 2011-06-13 | 2014-07-23 | 香港中文大学 | 基于小核酸药物成骨治疗的骨靶向递送系统及其制备方法 |
| WO2014033540A2 (en) * | 2012-08-28 | 2014-03-06 | The Governors Of The University Of Alberta | Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods of making and using thereof |
| EP3016674A4 (en) | 2013-06-23 | 2017-03-15 | Wisconsin Alumni Research Foundation | Alpha-/beta-polypeptide analogs of parathyroid hormone (pth) and method of using same |
| EP4137147A3 (en) * | 2015-03-03 | 2023-04-05 | Radius Health, Inc. | Uses of abaloparatide in reducing fracture risk |
| WO2016196400A1 (en) * | 2015-05-29 | 2016-12-08 | Purdue Research Foundation | Bone fracture repair by targeting of agents that promote bone healing |
| CN106039316B (zh) * | 2016-05-03 | 2019-04-02 | 同济大学 | 一种基于多肽构建的成骨细胞靶向载体及其制备与应用 |
| CA3045458A1 (en) * | 2016-11-30 | 2018-06-07 | Purdue Research Foundation | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
| WO2022093373A1 (en) * | 2020-10-26 | 2022-05-05 | Purdue Research Foundation | Compounds,compositions and methods of use to treat bone fractures |
-
2017
- 2017-11-30 CA CA3045458A patent/CA3045458A1/en active Pending
- 2017-11-30 JP JP2019529240A patent/JP7649624B2/ja active Active
- 2017-11-30 MX MX2019006189A patent/MX2019006189A/es unknown
- 2017-11-30 BR BR112019011070A patent/BR112019011070A2/pt active Search and Examination
- 2017-11-30 CN CN201780073942.4A patent/CN110114065A/zh active Pending
- 2017-11-30 US US16/464,164 patent/US20200317745A1/en not_active Abandoned
- 2017-11-30 EP EP17875427.1A patent/EP3548012A4/en active Pending
- 2017-11-30 AU AU2017367699A patent/AU2017367699B2/en active Active
- 2017-11-30 IL IL266977A patent/IL266977B2/en unknown
- 2017-11-30 WO PCT/US2017/064081 patent/WO2018102616A1/en not_active Ceased
-
2020
- 2020-03-31 US US16/836,366 patent/US10960054B2/en active Active
-
2021
- 2021-02-24 US US17/184,400 patent/US20210283227A1/en active Pending
-
2022
- 2022-12-02 JP JP2022193738A patent/JP2023029957A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210283227A1 (en) | 2021-09-16 |
| CA3045458A1 (en) | 2018-06-07 |
| RU2019119701A (ru) | 2021-01-14 |
| AU2017367699A1 (en) | 2019-07-11 |
| AU2017367699B2 (en) | 2023-12-07 |
| JP2020500871A (ja) | 2020-01-16 |
| RU2019119701A3 (enExample) | 2021-02-16 |
| BR112019011070A2 (pt) | 2019-10-01 |
| US20200316174A1 (en) | 2020-10-08 |
| EP3548012A4 (en) | 2020-07-22 |
| WO2018102616A1 (en) | 2018-06-07 |
| EP3548012A1 (en) | 2019-10-09 |
| JP2023029957A (ja) | 2023-03-07 |
| IL266977B1 (en) | 2023-09-01 |
| IL266977A (en) | 2019-07-31 |
| IL266977B2 (en) | 2024-01-01 |
| US10960054B2 (en) | 2021-03-30 |
| JP7649624B2 (ja) | 2025-03-21 |
| US20200317745A1 (en) | 2020-10-08 |
| CN110114065A (zh) | 2019-08-09 |
| AU2017367699A8 (en) | 2019-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019006189A (es) | Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea. | |
| IN2015DN03219A (enExample) | ||
| SG11201810939PA (en) | Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid | |
| MY191380A (en) | Stabilized fixed dose drug composition having mometasone and olopatadine | |
| MX350378B (es) | Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica. | |
| HK1211483A1 (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
| MX2018014279A (es) | Tratamiento terapeutico de cancer de mama con base en estado de c-maf. | |
| MX2020011333A (es) | Uso terapeutico de proteinas morfogeneticas oseas. | |
| EP4570317A3 (en) | Compounds for the treatment of bovine or swine respiratory disease | |
| MX2019013857A (es) | Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico. | |
| NZ721835A (en) | An osseointegrable device | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| BR112014021497A2 (pt) | sistema de entrega de fármaco baseado em jcv-vlp | |
| MX2017016418A (es) | Composiciones de liraglutida de acción prolongada. | |
| BR112017002878A2 (pt) | distribuição coordenada de tratamento de copd | |
| PH12016501733A1 (en) | Pharmaceutical composition for preventing or treating skin rash | |
| BR112019024875A2 (pt) | Métodos para o tratamento da ileíte do reservatório crônica | |
| EP3626712A3 (en) | Liver x receptor (lxr) modulators | |
| WO2020086479A9 (en) | Dosing | |
| WO2016026917A3 (en) | Medicament and apparatus for treating chronic kidney disease | |
| SG11201808253YA (en) | Marker for predicting treatment response to anti-cancer agent in solid cancer patients | |
| MX380088B (es) | Uso terapéutico de una solución oftálmica acuosa estéril. | |
| PH12018502195A1 (en) | Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases | |
| Avci | Ibandronic acid | |
| EP3159003A3 (en) | Composition for enhancing bone growth, preventing bone resorption disorders and for joint health |